Full Business Value: Hepion Pharmaceuticals (HEPA)

Hepion Pharmaceuticals (HEPA) management is currently liquidating the business due to failed drug trials and an inability to bring products to market. The confirmed price history on the GURU.Markets platform chart, where the Enterprise Value is , underscores the importance of strict control over the movement of therapy components. A total abandonment of tests due to their futility has led the company to financial collapse and the legal closure of all laboratories.

Against the backdrop of laboratory liquidations and cost reductions at Hepion Pharmaceuticals (HEPA), the enterprise value on this chart reflects the actual acquisition cost of the business, summing market capitalization and debt minus cash. This metric digitizes the residual value of assets following the failure of R&D trials, allowing investors to assess credit risk and the probability of a sharp valuation correction while seeking capital recovery options.